Design Therapeutics, Inc. (DSGN) Form 8-K — Nov 4, 2026
Design Therapeutics reported Q3 2026 financial results, posting a net loss of $20.3 million on R&D expenses of $16.9 million and G&A expenses of $5.3 million. The company ended the quarter with $208.6 million in cash, cash equivalents and investment securities, down from $219.8 million at year-end 2025, which management describes as providing a strong financial runway.
Key figures
- Revenue
- 0
- Total Debt
- 0
- Total Assets
- 216808000
- Cash Position
- 208608000
- Cash dec 31 2025
- 219845000
- Net loss q3 2025
- 16997000
- Ga expense q3 2026
- 5304000
- Rd expense q3 2026
- 16926000
- Net loss nine months 2026
- 58089000
- Weighted avg shares q3 2026
- 63035529
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.